Prognostic significance of bone marrow FDG uptake in patients with gynecological cancer

[1]  S. Mabuchi,et al.  The role of myeloid-derived suppressor cells in increasing cancer stem-like cells and promoting PD-L1 expression in epithelial ovarian cancer , 2020, Cancer Immunology, Immunotherapy.

[2]  J. Hatazawa,et al.  Pretreatment tumor-related leukocytosis misleads positron emission tomography-computed tomography during lymph node staging in gynecological malignancies , 2020, Nature Communications.

[3]  S. Mabuchi,et al.  The role of myeloid-derived suppressor cells in endometrial cancer displaying systemic inflammatory response: clinical and preclinical investigations , 2019, Oncoimmunology.

[4]  S. Mabuchi,et al.  Estrogen stimulates female cancer progression by inducing myeloid-derived suppressive cells: investigations on pregnant and non-pregnant experimental models , 2019, Oncotarget.

[5]  C. Haie-meder,et al.  Increased bone marrow SUVmax on 18F-FDG PET is associated with higher pelvic treatment failure in patients with cervical cancer treated by chemoradiotherapy and brachytherapy , 2019, Oncoimmunology.

[6]  E. Morii,et al.  Prostaglandin E2 produced by myeloid-derived suppressive cells induces cancer stem cells in uterine cervical cancer , 2018, Oncotarget.

[7]  S. Groshen,et al.  Predictive Value of FDG PET/CT to Detect Lymph Node Metastases in Cervical Cancer , 2018, Clinical nuclear medicine.

[8]  S. Woo,et al.  Performance of pre-treatment 18F-fluorodeoxyglucose positron emission tomography/computed tomography for detecting metastasis in ovarian cancer: a systematic review and meta-analysis , 2018, Journal of gynecologic oncology.

[9]  S. Mabuchi,et al.  Myeloid-derived suppressor cells and their role in gynecological malignancies , 2018, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

[10]  E. Morii,et al.  The Highly Metastatic Nature of Uterine Cervical/Endometrial Cancer Displaying Tumor-Related Leukocytosis: Clinical and Preclinical Investigations , 2018, Clinical Cancer Research.

[11]  S. Mabuchi,et al.  Comparison of clinical utility between neutrophil count and neutrophil–lymphocyte ratio in patients with ovarian cancer: a single institutional experience and a literature review , 2018, International Journal of Clinical Oncology.

[12]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[13]  S. Mabuchi,et al.  The Significance of Pretreatment Thrombocytosis and Its Association With Neutrophilia in Patients With Surgically Treated Endometrial Cancer , 2017, International Journal of Gynecologic Cancer.

[14]  Jeong Won Lee,et al.  Prognostic Value of Fluorine-18 Fluorodeoxyglucose Uptake of Bone Marrow on Positron Emission Tomography/Computed Tomography for Prediction of Disease Progression in Cervical Cancer , 2017, International Journal of Gynecologic Cancer.

[15]  H. Salvesen,et al.  High Diagnostic Value of 18F-FDG PET/CT in Endometrial Cancer: Systematic Review and Meta-Analysis of the Literature , 2016, The Journal of Nuclear Medicine.

[16]  E. Morii,et al.  The significance of G-CSF expression and myeloid-derived suppressor cells in the chemoresistance of uterine cervical cancer , 2015, Scientific Reports.

[17]  S. Mabuchi,et al.  Prognostic significance of systemic neutrophil and leukocyte alterations in surgically treated endometrial cancer patients: a monoinstitutional study. , 2015, Gynecologic oncology.

[18]  E. Morii,et al.  Uterine cervical cancer displaying tumor-related leukocytosis: a distinct clinical entity with radioresistant feature. , 2014, Journal of the National Cancer Institute.

[19]  D. Mutch,et al.  Pretreatment leukocytosis is an indicator of poor prognosis in patients with cervical cancer. , 2011, Gynecologic oncology.

[20]  Y. Takeda,et al.  Diagnostic value of FDG‐PET for lymph node metastasis and outcome of surgery for biliary cancer , 2011, Journal of surgical oncology.

[21]  S. Kinomura,et al.  A bone marrow F-18 FDG uptake exceeding the liver uptake may indicate bone marrow hyperactivity , 2009, Annals of nuclear medicine.

[22]  J. Philippé,et al.  FDG uptake by the bone marrow in NSCLC patients is related to TGF-β but not to VEGF or G-CSF serum levels , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[23]  Hiroshi Watanabe,et al.  Correlations between 18F-FDG uptake by bone marrow and hematological parameters: measurements by PET/CT. , 2006, Nuclear medicine and biology.

[24]  R. Wahl,et al.  Effects of pegfilgrastim on normal biodistribution of 18F-FDG: preclinical and clinical studies. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[25]  H. Hamada,et al.  Generation of fiber-mutant recombinant adenoviruses for gene therapy of malignant glioma. , 1998, Human gene therapy.

[26]  R. Samulski,et al.  Rescue of adeno-associated virus from recombinant plasmids: Gene correction within the terminal repeats of AAV , 1983, Cell.

[27]  S. Mabuchi,et al.  G-CSF induces focal intense bone marrow FDG uptake mimicking multiple bone metastases from uterine cervical cancer: a case report and review of the literature. , 2012, European journal of gynaecological oncology.

[28]  K. Hongo,et al.  A case report and review of the literature , 2006, Journal of Neuro-Oncology.

[29]  R. Wahl,et al.  Preclinical and clinical studies of bone marrow uptake of fluorine-1-fluorodeoxyglucose with or without granulocyte colony-stimulating factor during chemotherapy. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.